Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi's

Conference Proceedings

B Tran, F Meric-Bernstam, H-T Arkenau, R Bahleda, RK Kelley, C Hierro, D Ahn, A Zhu, M Javle, R Winkler, H He, J Huang, L Goyal

ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2018

Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd.